Journal of Clinical Investigation - Cardiology
OCTOBER 15, 2024
This Review will cover this topic from a variety of perspectives, with a particular emphasis on neurobiological findings and innovative treatment approaches that are being pursued. Although no pharmacological interventions are yet approved for CUD, we present the most promising pharmacological interventions being tested.
DAIC
FEBRUARY 27, 2024
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrial fibrillation (NVAF) treatment. The prospective, randomized, controlled, multicenter, open-label pivotal clinical study aims to enroll 1,500 patients across up to 100 sites in the United States.
The British Journal of Cardiology
AUGUST 14, 2024
Faculty member Affiliation Professor Amitava Banerjee Professor of Clinical Data Science, Institute of Health Informatics, University College London; Consultant Cardiologist, University College London Hospitals and Barts Health NHS Trust Professor Sir Mark Caulfield Professor of Clinical Pharmacology, Queen Mary Un.
HeartRhythm
APRIL 30, 2024
This innovation bottleneck may be attributed to the lack of a preclinical model that not only recapitulates human disease but is also suitable for empiric drug discovery.
Frontiers in Cardiovascular Medicine
JUNE 3, 2024
Despite extensive efforts to develop pharmacological treatments, there is currently no effective agent to prevent aneurysm growth and rupture. Abdominal aortic aneurysm (AAA) is a significant source of mortality worldwide and carries a mortality of greater than 80% after rupture.
DAIC
APRIL 3, 2024
The “Pharmacology Program” will cover hot topics in cardiovascular medicine that are key issues that pharmacists, as well as other health care team members, face in managing complex patients. Each session is interactive and includes knowledge check-ins and dedicated time for discussion. 24 news here.
Journal of Cardiovascular Pharmacology
OCTOBER 9, 2023
Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most important pharmacological innovations in the field of Cardiology of the last decades, having shown significant outcome improvement in all the heart failure (HF) spectrum. However, cost-effectiveness considerations should be made.
Expert insights. Personalized for you.
98 
Let's personalize your content